News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theravance, Inc. (THRX) Abandons ADHD Drug After Drug Fails Phase 2 Study


11/14/2013 8:05:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Today Rick E Winningham, Chief Executive Officer of Theravance, Inc. (Nasdaq: THRX) presented at the 2013 Credit Suisse Annual Health Care Conference in Scottsdale, Arizona. During the slide presentation, Mr. Winningham announced that TD-9855 did not meet the primary efficacy endpoint of symptom reduction as measured by AISRS (Adult Investigator Symptom Rating Scale) total score versus placebo in the Phase 2 study in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD). TD 9855 was generally well tolerated with no serious adverse events at either the 5 mg or 20 mg dose of TD-9855.

Help employers find you! Check out all the jobs and post your resume.

Read at Street Insider

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES